Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078458223> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2078458223 endingPage "2970" @default.
- W2078458223 startingPage "2966" @default.
- W2078458223 abstract "Etoposide, ifosfamide, and cisplatin (VIP) are each active in treating pediatric solid tumors, and this combination has been shown to be effective in treating adult germ cell tumors. Etoposide, ifosfamide, and cisplatin therapy was used to treat 11 patients, with ages ranging from 14 months to 22 years, with relapsed sarcoma, Wilm's tumor, and hepatoblastoma.Etoposide, ifosfamide, and cisplatin therapy was administered daily for 3 days in doses of cisplatin 20 mg/m2 with mannitol 10 g/m2 for 1 hour, etoposide 100 mg/m2, and ifosfamide 1.5 g/m2 with MESNA 360 mg/m2 x 3 doses. A total of 65 courses (range, 3-10/patient) were administered, with 86% of the courses administered at full dose. Hematopoietic growth factors were not used.All 10 evaluable patients responded. Six patients had a complete response (CR) by computed tomographic or magnetic resonance imaging scan after one to three courses. The remaining four patients had a partial response (PR) (> 50% decrease in disease). One PR was converted to a CR by resection of the residual lesions. The major toxicity was myelosuppression. The median nadirs after full doses were as follows: leukocyte count of 900/mm3, absolute neutrophil count (ANC) of 156/mm3, platelet count of 61,000/mm3, and hemoglobin count of 8.6 g/dl; 75% of full dose courses led to an ANC of less than 500. Fever and neutropenia were observed after 8/55 (15%) full dose courses. Two episodes of bacteremia were noted, one with Staphylococcus epidermidis after full recovery of counts. The median time to hematologic recovery was 21 days (range, 14-29 days). No patient developed a decreased creatinine clearance level during therapy. Significant renal solute losses were observed in two patients, both of whom had been pretreated heavily with ifosfamide and had losses before VIP therapy.Etoposide, ifosfamide, and cisplatin appear to be active in treating childhood solid tumors. This therapy has predictable and tolerable myelotoxicity, and nephrotoxicity does not appear to be more severe than that observed after treatment with ifosfamide alone." @default.
- W2078458223 created "2016-06-24" @default.
- W2078458223 creator A5011956202 @default.
- W2078458223 creator A5012975912 @default.
- W2078458223 creator A5023079518 @default.
- W2078458223 creator A5044469864 @default.
- W2078458223 date "1995-06-15" @default.
- W2078458223 modified "2023-09-24" @default.
- W2078458223 title "Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity" @default.
- W2078458223 cites W1803392829 @default.
- W2078458223 cites W1824837486 @default.
- W2078458223 cites W1860006956 @default.
- W2078458223 cites W1925062343 @default.
- W2078458223 cites W1968038860 @default.
- W2078458223 cites W1987061854 @default.
- W2078458223 cites W2030230730 @default.
- W2078458223 cites W2034481315 @default.
- W2078458223 cites W2070146394 @default.
- W2078458223 cites W2082425186 @default.
- W2078458223 doi "https://doi.org/10.1002/1097-0142(19950615)75:12<2966::aid-cncr2820751226>3.0.co;2-w" @default.
- W2078458223 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7773949" @default.
- W2078458223 hasPublicationYear "1995" @default.
- W2078458223 type Work @default.
- W2078458223 sameAs 2078458223 @default.
- W2078458223 citedByCount "19" @default.
- W2078458223 countsByYear W20784582232012 @default.
- W2078458223 countsByYear W20784582232014 @default.
- W2078458223 countsByYear W20784582232015 @default.
- W2078458223 countsByYear W20784582232019 @default.
- W2078458223 countsByYear W20784582232021 @default.
- W2078458223 crossrefType "journal-article" @default.
- W2078458223 hasAuthorship W2078458223A5011956202 @default.
- W2078458223 hasAuthorship W2078458223A5012975912 @default.
- W2078458223 hasAuthorship W2078458223A5023079518 @default.
- W2078458223 hasAuthorship W2078458223A5044469864 @default.
- W2078458223 hasConcept C126322002 @default.
- W2078458223 hasConcept C126894567 @default.
- W2078458223 hasConcept C141071460 @default.
- W2078458223 hasConcept C2776694085 @default.
- W2078458223 hasConcept C2776938808 @default.
- W2078458223 hasConcept C2777063308 @default.
- W2078458223 hasConcept C2777506904 @default.
- W2078458223 hasConcept C2778119113 @default.
- W2078458223 hasConcept C2778239845 @default.
- W2078458223 hasConcept C2780376820 @default.
- W2078458223 hasConcept C71924100 @default.
- W2078458223 hasConcept C74133956 @default.
- W2078458223 hasConcept C90924648 @default.
- W2078458223 hasConceptScore W2078458223C126322002 @default.
- W2078458223 hasConceptScore W2078458223C126894567 @default.
- W2078458223 hasConceptScore W2078458223C141071460 @default.
- W2078458223 hasConceptScore W2078458223C2776694085 @default.
- W2078458223 hasConceptScore W2078458223C2776938808 @default.
- W2078458223 hasConceptScore W2078458223C2777063308 @default.
- W2078458223 hasConceptScore W2078458223C2777506904 @default.
- W2078458223 hasConceptScore W2078458223C2778119113 @default.
- W2078458223 hasConceptScore W2078458223C2778239845 @default.
- W2078458223 hasConceptScore W2078458223C2780376820 @default.
- W2078458223 hasConceptScore W2078458223C71924100 @default.
- W2078458223 hasConceptScore W2078458223C74133956 @default.
- W2078458223 hasConceptScore W2078458223C90924648 @default.
- W2078458223 hasIssue "12" @default.
- W2078458223 hasLocation W20784582231 @default.
- W2078458223 hasLocation W20784582232 @default.
- W2078458223 hasOpenAccess W2078458223 @default.
- W2078458223 hasPrimaryLocation W20784582231 @default.
- W2078458223 hasRelatedWork W1975212853 @default.
- W2078458223 hasRelatedWork W1998553286 @default.
- W2078458223 hasRelatedWork W2018507611 @default.
- W2078458223 hasRelatedWork W2025027408 @default.
- W2078458223 hasRelatedWork W2040951017 @default.
- W2078458223 hasRelatedWork W2415870516 @default.
- W2078458223 hasRelatedWork W2466567915 @default.
- W2078458223 hasRelatedWork W2789166760 @default.
- W2078458223 hasRelatedWork W5464812 @default.
- W2078458223 hasRelatedWork W2055644606 @default.
- W2078458223 hasVolume "75" @default.
- W2078458223 isParatext "false" @default.
- W2078458223 isRetracted "false" @default.
- W2078458223 magId "2078458223" @default.
- W2078458223 workType "article" @default.